Abstract:Abstract Background and Aims A new eGFR equation using serum creatinine (CKD-EPI 2021) without race were developed by Chronic Kidney Disease Epidemiology Collaboration in 2021. We projected the changes of eGFR, CKD prevalence, and incidence of end stage renal disease (ESRD) and mortality in a large prospective cohort of adult Koreans who had voluntary health check-ups, using current (CKD-EPI 2009) and new equation (CKD-EPI 2021). Method We included 112,772 adult participants, aged 18 years or older, who had voluntary routine health check-ups including serum creatinine at three medical centers in Korea from 2003 to 2009. We compared the difference of eGFR and predictability of mortality and ESRD between eGFR values calculated by CKD-EPI 2009 and CKD-EPI 2021. Serum creatinine was expressed as the IDMS-traceable creatinine according to the manufacturer's conversion formula from the original value measured by the alkaline picrate Jaffe kinetic method. The incidence of mortality data was extracted from Statistics Korea and the ESRD data from the ESRD registry of the Korean Society of Nephrology. Results At baseline study, there were 60,723 males (53.8%). Age was 48.9 ± 12.0 years. The value of IDMS-traceable serum creatinine was 0.86 ± 0.21 mg/dl. Levels of eGFR at baseline study were 93.5 ± 15.6 ml/min/1.73 m2 by CKD-EPI2009, and 97.1 ± 15.0 ml/min/1.73 m2 by CKD-EPI2021. Values subtracted eGFRs by CKD-EPI2009 from eGFR by CKD-EPEI2021 were 3.6 ± 1.2 (range: -32.9∼6.1) ml/min/1.73 m2. The difference of eGFR was higher in males compared to females (p<0.001), was the highest in the oldest group among patients aged 18–44 years, 45–64 years, and 65 years or more (p<0.001). Patients with diabetes mellitus (DM) or hypertension showed higher difference of eGFR compared patients without DM or hypertension, respectively (each p<0.001). Patients with eGFR ≥120.0 ml/min/1.73 m2 by CKD-EPI 2009 showed the highest difference between two eGFRs compared to patients with the other values. CKD stage was improved in 11,828 (10.5%) participants using eGFR calculated by CKD-EPI 2021 instead of CKD-EPI 2009, however, only 0.63% of participants with eGFR <60 ml/min/1.73 m2 by CKD-EPI equation was reclassified into eGFR ≥60 ml/min/1.73 m2 by CKD-EPI 2021.During 11.6 ± 2.0 years, 3354 (3.00%) subjects were dead and 151 (0.13%) subjects had end stage renal disease (ESRD) before death. Any eGFR or stage of eGFR was an independent risk factors to ESRD or mortality estimated by Cox's hazard proportional model adjusted by related factors. AUC to estimate renal survival by eGFRs was not different between eGFRs by CKD-EPI2021 and CKD-EPI2009 [0.739 (0.687-0.790) vs 0.740(0.688-0.792), p = 0.170]. p<0.001]. AUC to estimate survival by eGFRs calculated through CKD-EPI equation was slightly higher than that by CKD-EPI2021 equation [0.673(0.664-0.682) vs 0.667(0.658-0.676), p<0.001], however, the difference of AUC was negligible [standard error of AUC difference by two eGFRs; 0.96 (95% CI; 0.006-0.007)]. Conclusion The eGFR calculated by CKD-EPI2021 was higher compared to eGFR calculated by CKD-EPI2009. The power to estimate renal survival was not different between eGFRs by CKD-EPI2021 and CKD-EPI2009.

Clinical implications of the CKD epidemiology collaboration (CKD-EPI) equation compared with the modification of diet in renal disease (MDRD) study equation for the estimation of renal dysfunction in patients with cardiovascular disease

Passaggio dalla formula MDRD alla CKD-EPI: impatto sulla riclassificazione in stadi della malattia renale cronica

Application of MDRD and CKD-EPI Equations in Patients with Peripheral Arterial Diseases

Chronic kidney disease and prognosis in elderly patients with cardiovascular disease: Comparison between CKD-EPI and Berlin Initiative Study-1 formulas

Comparison of the Heart Failure Risk Stratification Performance of the CKD–EPI Equation and the MDRD Equation for Estimated Glomerular Filtration Rate in Patients with Type 2 Diabetes

Impact of the New CKD-EPI Equation on the Staging of Patients with Chronic Kidney Disease Based on Abbreviated MDRD Equation

The Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) equation does not improve the underestimation of Glomerular Filtration Rate (GFR) in people with diabetes and preserved renal function

Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) Equation Pronouncedly Underestimates Glomerular Filtration Rate in Type 2 Diabetes

Diagnostic performance of the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation at estimating glomerular filtration rate in adults with diabetes mellitus: a systematic review and meta-analysis protocol

The CKD-EPI 2021 Equation and Other Creatinine-Based Race-Independent eGFR Equations in Chronic Kidney Disease Diagnosis and Staging

Collaboration equation for estimating glomerular fi ltration rate in the Chinese population

Observations from a teaching hospital in Ireland: changing from MDRD to CKD-EPI eGFR in routine practice

CKD-EPI and EKFC GFR Estimating Equations: Performance and Other Considerations for Selecting Equations for Implementation in Adults

Comparison of three creatinine-based equations to predict adverse outcome in a cardiovascular high-risk cohort: an investigation using the SPRINT research materials

Cystatin C-based CKD-EPI Estimated Glomerular Filtration Rate Equations As a Better Strategy for Mortality Stratification in Acute Heart Failure

#3619 CKD EPI 2021 EQUATION FOR EGFR HAS GOOD EFFICACY TO PREDICT CLINICAL OUTCOMES IN A LARGE PROSPECTIVE COHORT OF ADULT KOREANS

Comparisons between the 2012 New CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) Equations and Other Four Approved Equations

Contribution of cystatin C- and creatinine-based definitions of chronic kidney disease to cardiovascular risk assessment in 20 population-based and 3 disease cohorts: the BiomarCaRE project

High Incidence of Chronic Kidney Disease among Iranian Diabetic Adults: Using CKD-EPI and MDRD Equations for Estimated Glomerular Filtration Rate

MDRD vs. CKD-EPI in comparison to 51Chromium EDTA: a cross sectional study of Malaysian CKD cohort

410-P: Evaluating the Performance of the 2021 CKD–EPI Equation in People with Diabetes